Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genta appealing Genasense "not approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genta announces Feb. 6 that it will appeal FDA's December 2006 "not approvable" designation for use of its oncologic Genasense (oblimersen) in chronic lymphocytic leukemia. "The appeal will be filed pursuant to the Formal Dispute Resolution process that exists within FDA's Center for Drug Evaluation and Research," Genta stated, adding that it filed notice reserving its rights to appeal in December 2006 and expects to complete the filing of this appeal during the current calendar quarter. Genta received the not approvable letter for the CLL indication in mid-December. The firm is also investigating the Bcl-2 inhibitor's utility in melanoma; a Phase III combination study in advanced melanoma was initiated in November (1Pharmaceutical Approvals Monthly December 2006, In Brief)...

You may also be interested in...

Genta starts Genasense melanoma combination study

Genta has initiated a new clinical study to evaluate its Bcl-2 inhibitor Genasense (oblimersen) in patients with advanced melanoma, the company announces Nov. 29. The trial is the first follow-on study to Genta's Phase III advanced melanoma trial of Genasense plus dacarbazine. The new pilot study will evaluate safety, efficacy and pharmacokinetics of Genasense combined with Abraxis BioScience's Abraxane (paclitaxel protein-bound particles) and Schering-Plough's Temodar (temozolomide). Meanwhile, Genta saw a setback Dec. 8 when preliminary results of a Phase III study of Genasense in acute myeloid leukemia failed to reach the overall survival primary endpoint. The company's NDA for chronic lymphocytic leukemia has a user fee date of Jan. 29 (1Pharmaceutical Approvals Monthly November 2006, In Brief)...

Siegfried Reaches ‘Next Level’ As Sales And Profits Lift

Swiss company Siegfried has seen an increase in sales, EBITDA and net profit in 2020 and expects its turnover to exceed CHF1bn this year. The firm is also looking to execute on its partnership with BioNTech on filling and packaging the firm’s COVID-19 vaccine.

COVID-19 Tests: How The EU Rules Are Changing And Where Questions Still Lie

There are very few regulatory hurdles to placing a COVID-19 test on the EU market under the IVD Directive. This situation, however, is changing under the IVD Regulation. The European Commission explains what manufacturers need to weigh up when deciding their regulatory pathway.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts